Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

• Principais autores: Bárbara Lima (Autor), Miguel Henriques Abreu (Autor), Susana Sousa (Autor), Carla Bartosch (Autor), Deolinda Pereira (Autor)
• Formato: Livro
• Publicado em: Elsevier, 2022-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinas...